The effectiveness results were as follows:
mean increase in morning PEFR (L/min), 51.6 in the FP group versus 26.9 in the FL group (p<0.01) in the open-label study, and 41.0 in the FP group versus 29.0 in the FL group (p<0.01) in the double-blind study;
mean increase in evening PEFR (L/min), 42.3 in the FP group versus 22.5 in the FL group (p<0.01) in the open-label study, and 37.0 in the FP group versus 31.0 in the FL group (p<0.01) in the double-blind study;
proportion of successfully treated patients, 56.8% in the FP group versus 39.6% in the FL group in the open-label study, and 55.3% in the FP group versus 44.5% in the FL group in the double-blind study;
increase over baseline in proportion of symptom-free days (SFD), 30.2% in the FP group versus 21.1% in the FL group in the open-label study, and 25.7% in the FP group versus 20% in the FL group in the double-blind study;
and proportion of SFD at the end of study, 36.4% in the FP group versus 28.5% in the FL group in the open-label study, and 35.1% in the FP group versus 31.1% in the FL group in the double-blind study.